This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 14-21 October 2008.
THIOTEPA

Thiotepa was considered by a previous IARC Working Group in 1989 (IARC, 1990). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation.

1. Exposure Data

1.1 Identification of the agent

Chem. Abstr. Serv. Reg. No.: 52-24-4
Chem. Abstr. Name: Aziridine, 1,1′,1″-phosphinothioylidynetris-
IUPAC Systematic Name: tris(Aziridin-1-yl)-sulfanylidene\(\lambda^5\)phosphane
Synonyms: Phosphorothioic acid tri-ethylenetriamide; phosphorothioic tri-amide, \(N,N',N''\)-tri-1,2-ethanediyl-; thiophosphamide; thiophosphoramid e, \(N,N',N''\)-tri-1,2-ethanediyl-; Thioplex; thiotriethylenephosphoramide; \(N,N',N''\)-triethylenthiophosphoramide; tri(ethyleneimino)thiophosphoram id; tri-1-aziridinylphosphine sulfide; tri-aziridinylphosphine sulfide; triethylenthiophosphoram ide; triethylenthiophosphorotriamide; tris(1-aziridinyl)phosphine sulfide; tris(aziridinyl)phosphine sulfide
Description: Fine, white, crystalline flakes with a faint odour (McEvoy, 2007)

1.1.1 Structural and molecular formulae, and relative molecular mass

\[
\begin{align*}
\text{N} & \quad \text{P} \\
\text{N} & \quad \text{N}
\end{align*}
\]
\(C_6H_{12}N_3PS\)
Relative molecular mass: 189.22

1.2 Use of the agent


1.2.1 Indications

Thiotepa has been used intravesically for the treatment of residual tumours and as adjuvant therapy for prophylaxis of superficial bladder cancer. Thiotepa has also been used parenterally in the palliative treatment of adenocarcinoma of the breast and ovary. Thiotepa may be used by intracavitary injection to control pleural, pericardial, or peritoneal effusions caused by metastatic tumours.
1.2.2 Dosage

Thiotepa may be administered by intravenous, intramuscular, intrapleural, intraperitoneal, intrapericardial or intratumour injection, or by intravesical instillation.

Thiotepa may be given rapidly intravenously in doses of 0.3–0.4 mg/kg at intervals of 1–4 weeks. The drug has also been given intravenously in doses of 0.2 mg/kg or 6 mg/m² daily for 4 or 5 days at intervals of 2–4 weeks. Thiotepa has also been given intramuscularly in doses of 15–30 mg in various schedules.

The usual intracavitary dose of thiotepa is 0.6–0.8 mg/kg at intervals of at least 1 week, although a dose of 15–30 mg has been used intrapericardially.

For the treatment of superficial bladder tumours, the dose of thiotepa generally ranges from 30–60 mg, instilled by catheter in saline directly into the bladder. The usual course of treatment is once a week for 4 weeks. Single doses of 90 mg in 100 mL of sterile water have also been used prophylactically following local resection.

For malignant effusions, doses of up to 60 mg of thiotepa in 20–60 mL of sterile water may be instilled after aspiration; in the USA, the licensed dose is 0.6–0.8 mg/kg, a dose similar to that suggested for injection directly into tumours.

Thiotepa is available as 15 and 30 mg solutions for parenteral administration.

1.2.3 Trends in use

Although thiotepa has largely been replaced by the nitrogen mustards, it still has specific uses, particularly as a component of experimental high-dose chemotherapy regimens.

2. Cancer in Humans

Several cases of leukaemia following treatment with thiotepa alone have been reported. As was the case in the previous IARC Monograph (IARC, 1990), only one analytical study focused specifically on the cancer risk of thiotepa in humans (Kaldor et al., 1990). This study, which used a case–control methodology within a cohort of women treated for ovarian cancer, found a strong association between the risk for leukaemia and treatment with thiotepa with a relative risk of 8.3 in the lower dose group (n = 4), and 9.7 in the higher dose group (n = 5).

3. Cancer in Experimental Animals

Thiotepa was tested for carcinogenicity by intraperitoneal administration in mice and rats, and by intravenous administration in male rats (Table 3.1).

It increased the incidence of lung tumours and malignant lymphomas in mice of each sex. In rats, intraperitoneal administration increased the incidence of lymphohaematopoietic malignancies in males and of uterine adenocarcinomas and mammary carcinomas in females. Squamous cell carcinomas of the skin or ear were also induced in both sexes. Intravenous administration to male rats induced tumours at a variety of sites (IARC, 1990).

Since the previous IARC Monograph (IARC, 1990), a study with CB6F1-TgHras2 transgenic (rasH2) mice was performed during an interlaboratory validation study. Thiotepa was intraperitoneally administered to two groups of 15 male and 15 female rasH2 mice, 7–9 weeks of age, at doses of 1 and 2 mg/kg bw, 3 times per week for 24 weeks. Two similar groups of wild-type mice were also treated, and two groups of ten male and ten female rasH2 and wild-type mice served as vehicle controls. Forestomach papillomas, lung
<table>
<thead>
<tr>
<th>Species, strain (sex)</th>
<th>Duration</th>
<th>Reference</th>
<th>Route</th>
<th>Dosing regimen</th>
<th>Animals/group at start</th>
<th>Incidence of tumours</th>
<th>Significance</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse, A/He (M,F)</td>
<td>24 wk</td>
<td>Stoner et al. (1973)</td>
<td>i.ep.</td>
<td>0 (untreated), 0.19, 47, 94 (total dose) mg/kg bw (total 12 doses) 3×/wk for 4 wk</td>
<td>100, 160, 20, 20</td>
<td>Lung:</td>
<td>P &lt; 0.05 (94 mg/kg bw)</td>
<td>95~99% pure</td>
</tr>
<tr>
<td>Mouse, B6C3F1 (M,F)</td>
<td>86 wk</td>
<td>NCI (1978)</td>
<td>i.ep.</td>
<td>0, 1.15, 2.3 mg/kg bw 3×/wk for 52 wk</td>
<td>15, 15, 35, 35</td>
<td>Malignant lymphomas: M–1/18, 1/8, 2/24, 26/28</td>
<td>P &lt; 0.001 (2.3 mg/kg bw)</td>
<td>98 ± 1% pure</td>
</tr>
<tr>
<td>Rat, Sprague-Dawley (M,F)</td>
<td>86 wk</td>
<td>NCI (1978)</td>
<td>i.ep.</td>
<td>0, 0.7, 1.4, 2.8 mg/kg bw</td>
<td>20+20, 39, 35, 35</td>
<td>Myeloid leukaemia / malignant lymphomas: M–0/29 vs 6/34 (0.7 mg/kg)</td>
<td>P = 0.001</td>
<td>98 ± 1% pure</td>
</tr>
<tr>
<td>Rat, BR 46 (M)</td>
<td>52 wk</td>
<td>Schmähl &amp; Osswald (1970), Schmähl (1975)</td>
<td>i.v.</td>
<td>0, 1 mg/kg bw, weekly for 52 wk</td>
<td>0.7, 48</td>
<td>Malignant tumours: M–1/18 vs 6/34</td>
<td>P &lt; 0.01</td>
<td>&gt; 98% pure</td>
</tr>
</tbody>
</table>

* i.ep. = intraperitoneal; i.v. = intravenous; M, male; vs, versus; wk, week or weeks
adenomas, and thymic lymphomas were induced in both treated \( \text{rasH2} \) and wild-type mice. Lung adenocarcinomas were observed only in treated \( \text{rasH2} \) mice. There was a higher incidence of forestomach papillomas in male \( \text{rasH2} \) mice treated with 2 mg/kg thiotepa than in the corresponding wild-type mice and \( \text{rasH2} \) controls. The increase in the incidence of forestomach papillomas was dose-dependent in \( \text{rasH2} \) mice (Yamamoto et al., 1998a, b). [The Working Group noted the limited reporting of the study, i.e., no tumour incidences were provided.]

4. Other Relevant Data

4.1 Absorption, distribution, metabolism, and excretion

In humans, intravenous injection of thiotepa results in a peak blood concentration of thiotepa within 5 minutes, and after intraperitoneal administration, the peak plasma concentration is reached within 25 minutes. Distribution of thiotepa is rapid and is followed by fast elimination from the plasma compartment, with a half-life of 1–3 hours. Triethylenephosphoramide (TEPA), a metabolite of thiotepa, is detected in plasma 5–10 minutes after intravenous injection, and persists longer in plasma with a half-life of 3–21 hours. Both thiotepa and TEPA penetrate the cerebrospinal fluid (IARC, 1990; Maanen et al., 2000).

The urinary excretion of unchanged thiotepa is approximately 0.1–1.5% of the total administered thiotepa, and that of TEPA, 0.2–25%. Thiotepa can form conjugates with glutathione, and can be excreted as a thiotepa-mercapturic acid conjugate in the urine (Maanen et al., 2000).

Following thiotepa administration to rodents (intraperitoneal or intravenous injection), thiotepa is distributed rapidly to different organs, with most available for metabolism in the liver (IARC, 1990; Maanen et al., 2000). Many metabolic studies of thiotepa in various species (rat, dog, rabbit, and humans) have resulted in the identification of TEPA as the major metabolite of thiotepa. The metabolism of thiotepa to TEPA is mediated by hepatic cytochrome P450 (CYP) (Teicher et al., 1989; Hagen et al., 1991; Chang et al., 1995).

Plasma elimination of thiotepa after intravenous administration to mice follows a two-compartment model. The half-life is 0.21 minutes for the first phase, and 9.62 minutes for the second. The major urinary metabolite in rats, rabbits, and dogs following intravenous injection of \( ^{32} \text{P}-\text{thiotepa} \) is TEPA. However, most of the radioactivity in mouse urine is recovered as inorganic phosphate. TEPA is largely excreted unchanged after administration to rats, and 5–30% is converted to phosphate (IARC, 1990; Maanen et al., 2000).

4.2 Genotoxic effects

4.2.1 Interaction with DNA

Both thiotepa and TEPA are alkylating agents. As alkylating agents, these compounds are potentially trifunctional. The principal site of reaction in DNA is the \( N^7 \) position of guanine. Hydrolysis of thiotepa and TEPA produces aziridine (ethylenimine), a reactive monofunctional alkylating agent, that reacts to form 7-(2-aminomethyl)deoxyguanosine in DNA, which is an unstable adducted base that leads to depurinated sites (Musser et al., 1992). An aminoethyl-\( N^3 \)-adenine adduct is also formed (Andrievsky et al., 1991; Musser et al., 1992). Thiotepa can also act as a bifunctional alkylating agent, forming interstrand cross-links between guanine bases (at the \( N^7 \) position) of DNA (Maanen et al., 2000).

In common with other alkylating agents, therapeutic cytotoxicity is accompanied by mutagenic damage (Sanderson & Shield, 1996). Thiotepa cytotoxicity is attenuated by DNA
repair, principally base-excision repair (Limp-Foster & Kelley, 2000; Kobune et al., 2001; Xu et al., 2001), and inhibition of DNA-repair processes enhances cytotoxicity (Frankfurt, 1991; Frankfurt et al., 1993). However, lymphoblastoid cell lines derived from patients with Fanconi anaemia are hypersensitive to thiotepa (but not TEPA), implying the formation of interstrand cross-links (Cohen et al., 1991). Cells that are defective in p53 are also more sensitive to thiotepa (Seo et al., 2002).

4.2.2 Mutagenic effects

(a) Mutagenicity in vitro

In the previous IARC Monograph (IARC, 1990), it was reported that the compound induced gene mutations in Salmonella typhimurium and Aspergillus nidulans, and chromosomal aberrations and sister chromatid exchange in root meristem cells of Vicia faba. It also induced gene mutations, unscheduled DNA synthesis, micronuclei, sister chromatid exchange, and chromosomal aberrations in mammalian cells in vitro. It also induced morphological transformation of mouse cells. One study reported that thiotepa did not induce significant levels of DNA damage in rat or human testicular cells at up to 1000 µM (Bjørge et al., 1996), measured as single-strand breaks and alkali-labile sites by alkaline elution.

(b) Mutagenicity in vivo

Studies of mutant frequencies in the endogenous hypoxanthine(guanine)phosphoribosyl transferase (Hprt) and the transgenic LacI gene of Big Blue rats have found that thiotepa induced more mutations in Hprt than in LacI (Chen et al., 1998). The most common mutation was GC→TA transversions. Hprt mutations in lymphocytes were also analysed in Fischer 344 rats treated with thiotepa or TEPA, where GC→TA transversions were also the most common mutations observed (Casciano et al., 1999; Chen et al., 1999).

In the previous IARC Monograph (IARC, 1990), thiotepa induced micronuclei in the bone marrow of rats and mice, chromosomal aberrations in mouse bone-marrow and liver cells, and in peripheral lymphocytes of rhesus monkeys and rabbits. It also caused sister chromatid exchange in mouse bone marrow in vivo. Increased frequencies of chromosomal aberrations were observed in peripheral lymphocytes of patients receiving thiotepa therapy.

Subsequent studies have reported that thiotepa induces chromosomal aberrations in bone-marrow cells of Armenian hamsters (Cricetulua migratorius), although at a lower frequency than in other rodents (Nersessian, 1994).

When administered to rhesus monkeys (Macaca mulatta) by bolus injection, thiotepa was more cytotoxic (chromosomal aberrations in bone marrow) than when the same dose was given by continuous infusion over 96 hours (Rao et al., 2005). The induction of chromosomal aberrations and sister chromatid exchange in rhesus monkeys by intravenous injection of thiotepa led to an increase of the number of both sister chromatid exchange and chromosomal aberrations 14 hours after injection after which these levels began to fall. Sister chromatid exchange frequency reached control levels after 1 month, whereas chromosomal aberration frequency remained elevated after 6 months (Kuzin et al., 1989). The dietary antimutagens chlorophyllin, β-carotene and α-linolenic acid inhibited thiotepa-induced chromosomal aberrations in Chinese hamsters by up to 85% (Renner, 1990).

Thiotepa was reported previously to induce chromosomal aberrations in germ cells, sperm abnormalities, and dominant lethal mutation in mice in vivo (IARC, 1990). In a subsequent study, thiotepa was reported to give similar yields of dominant lethal mutations in different strains of mice (Lyon & Glenister, 1991), in contrast to earlier reports showing differences among strains (Surkova & Malashenko, 1975, 1977). Subsequent studies have also reported that thiotepa produced
very low yields of translocations in mouse stem cells (De Luca et al., 1990).

Thiotepa induced chromosomal aberrations in the reproductive cells of the female yellow fever mosquito (Aedes aegypti) (Puttaraju, 1994).

4.3 Synthesis

Thiotepa is an alkylating agent that is carcinogenic via a genotoxic mechanism.

5. Evaluation

There is sufficient evidence in humans for the carcinogenicity of thiotepa. Thiotepa causes leukaemia.

There is sufficient evidence in experimental animals for the carcinogenicity of thiotepa.

Thiotepa is carcinogenic to humans (Group 1).

References


De Luca JC, Dufout FN, Ulrich MA et al. (1990). The induction of reciprocal translocations in mouse germ cells by chemicals and ionizing radiations. II. Combined effects of mitomycin C or thio-tepa with two doses of gamma-rays. Mutat Res, 232: 11–16. PMID:2117707


Thiotepa
